COVID‐19 is associated with significant hypercoagulability. However, despite prophylactic anticoagulation, critically‐ill patients with this condition develop thromboses. This forum discusses the lungs as the epicentre for the haemostatic issues, put forwards a proposal for staging COVID‐19 coagulopathy based on available diagnostic markers, and suggest considering current and future treatment options based on these different stages.